your oatmeal tolerance may differ from another patient's based on genetics, baseline metabolism, and GI sensitivity
It's a fabulous, fabulous masterclass
doi: 10.1016/j.xcrm.2021.100263 74 VniantMMLuSCAtanganLKomorowskiRStanislausSChengYet al
Semaglutide not only improves glycemic control, evidenced by significant reductions in HbA1c (e.g., 0.54-0.6% in T1D and 1.2-1.8% in T2D) and fasting glucose, but also positively influences body composition by reducing fat mass, particularly visceral fat, while largely preserving lean muscle mass
Lydia Alexander, chief medical officer of the weight care platform Enara Health, and Robert Deshaies, chief operating officer of the benefits business at fintech company WEX) discussed employers new realityand the financial and population health implications of their next moves
By 2029, there will be around 40 million global users of the GLP-1 drug, forecasts a UBS Investment Bank report